To assess differences in baseline and longitudinal quality of life among Black and White individuals in the US with advanced prostate cancer.
Secondary analysis of data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN) including US participants newly diagnosed with advanced prostate cancer and identifying their race as Black or White from 2017 to 2023. Participants completed the EORTC QLQ-C30 Quality of Life (QoL) Survey at study enrollment and every 3 months thereafter for up to 1 year of follow-up reporting 15 scale scores ranging from 0 to 100 (higher functioning and lower symptom scores represent better quality of life). Linear mixed effects models with race and month of questionnaire completion were fit for each scale, and model coefficients were used to assess differences in baseline and longitudinal QoL by race.
Eight hundred and seventy-nine participants were included (20% identifying as Black) at 38 US sites. Compared to White participants at baseline, Black participants had worse constipation (mean 6.3 percentage points higher; 95% CI 2.9-9.8), financial insecurity (5.7 (1.4-10.0)), and pain (5.1 (0.9-9.3)). QoL decreased over time similarly by race; most notably, role functioning decreased by 0.7 percentage points (95% CI -0.8, -0.5) per month.
There are notable differences in quality of life at new diagnosis of advanced prostate cancer for Black and White individuals, and quality of life declines similarly in the first year for both groups. Interventions that address specific aspects of quality of life in these patients could meaningfully improve the overall survivorship experience.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2023 Jul 06 [Epub ahead of print]
Emily M Rencsok, Natalie Slopen, Karen Autio, Alicia Morgans, Lawrence McSwain, Pedro Barata, Heather H Cheng, Robert Dreicer, Elisabeth Heath, Rana R McKay, Mark Pomerantz, Dana Rathkopf, Scott Tagawa, Young E Whang, Camille Ragin, Folakemi T Odedina, Daniel J George, Philip W Kantoff, Jacob Vinson, Paul Villanti, Sebastien Haneuse, Lorelei A Mucci, IRONMAN Registry
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ., Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Memorial Sloan Kettering Cancer Center, New York, NY, USA., Dana-Farber Cancer Institute, Boston, MA, USA., , Durham, NC, USA., Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, LA, USA., Division of Medical Oncology, University of Washington, Seattle, WA, USA., University of Virginia Cancer Center, Charlottesville, VA, USA., Karmanos Cancer Institute, Detroit, MI, USA., Department of Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA, USA., Division of Hematology and Medical Oncology, Weill Cornell Medical Center, New York, NY, USA., Department of Medicine, Division of Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA., Fox Chase Cancer Center, Philadelphia, PA, USA., Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL, USA., Duke Cancer Institute, Durham, NC, USA., Prostate Cancer Clinical Trials Consortium (PCCTC), New York, NY, USA., Movember Foundation, Melbourne, Australia., Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.